Clinical Efficacy of Intravitreal Ranibizumab in Early and Mid-Idiopathic Choroidal Neovascularization

Table 1

A comparison of baseline clinical characteristics.

	Early group (𝑛=24)	Mid group (𝑛=20)	𝑃 value
Age (years)	31.8±7.8	34.3±8.9	0.326
Sex (male/female)	8/16	7/13	0.908
Subfoveal/juxtafoveal	13/11	12/8	0.697
Intraocular pressure (mmHg)	13.9±4.1	15.2±3.9	0.291
Refractive error (diopters)	−1.73±1.9	−2.43±2.1	0.253
Axial length (mm)	24.4±1.4	24.8±1.8	0.412
CMT before injection	368.2±96.9	443.3±126.1	0.031
BCVA (ETDRS)	67.9±13.1	42.3±24.8	0.001
Duration of CNV (days)	35.3±16.9	114.8±28.6	0.001